Grant: Project Grant - PA: Nutrition, Metabolism and Diabetes
University of Calgary
$100,000.00
Scalable production, delivery and assessment of human pseudoislets for research and clinical applications
EF 2018-19
Résumé
Type 1 diabetes is caused by the loss of the insulin-producing beta cells. Located within "islets" in the pancreas, they detect levels of blood sugar, and release insulin as needed. Without them, patients must test their own blood sugar levels and then calculate and inject themselves with appropriate quantity of insulin. Without the precise, continuous monitoring and correction of the natural process, patients can experience dangerous blood sugar highs and lows, with some suffering severe and potentially even fatal consequences.
Research using donated human islets is extremely important to understand diabetes - however supplies are very limited, unpredictable, and the donated material generally does not last more than a week or so. In the clinic, islet transplantation is a promising and effective treatment option for patients with type 1 diabetes, particularly those at high risk of sever low-blood-sugar events, but the problem of limited supply is made even worse by inefficient islet survival - when they are removed from an organ donor and lose their capillaries (blood vessels) many of the cells in the interior of larger islets are too far from the surface to receive enough oxygen and nutrients. This challenge gets even more pronounced after transplantation when the islets become buried in blood clots and tissues.
We have recently shown that we can use a microscale tissue engineering system we previously developed to remake islets into smaller, size controlled "pseudoislets". These last longer than the islets from which they are made, and function effectively both in culture, and in mice with induced diabetes. In the work proposed here we will establish ways to generate our pseudoislets in the quantities that will be needed for research and to treat patients; we will create processes to freeze, store and deliver them when and where they are needed; and we will develop quality control procedures to ensure the material is reliably safe and effective.
Programme
Project Grant - PA: Nutrition, Metabolism and Diabetes
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
395201
Name
Ungrin Mark D
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
Biomedical Engineering
Projecttitle
Scalable production, delivery and assessment of human pseudoislets for research and clinical applications
Programtype2
Operating Grants
Orgnameinp2
University of Calgary
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Project Grant - PA: Nutrition, Metabolism and Diabetes
Keyworddelim
Aggregation; Diabetes; Islet Transplantation; Microscale Tissue Engineering; Organoid; Translation
Abstract
Type 1 diabetes is caused by the loss of the insulin-producing beta cells. Located within "islets" in the pancreas, they detect levels of blood sugar, and release insulin as needed. Without them, patients must test their own blood sugar levels and then calculate and inject themselves with appropriate quantity of insulin. Without the precise, continuous monitoring and correction of the natural process, patients can experience dangerous blood sugar highs and lows, with some suffering severe and potentially even fatal consequences.
Research using donated human islets is extremely important to understand diabetes - however supplies are very limited, unpredictable, and the donated material generally does not last more than a week or so. In the clinic, islet transplantation is a promising and effective treatment option for patients with type 1 diabetes, particularly those at high risk of sever low-blood-sugar events, but the problem of limited supply is made even worse by inefficient islet survival - when they are removed from an organ donor and lose their capillaries (blood vessels) many of the cells in the interior of larger islets are too far from the surface to receive enough oxygen and nutrients. This challenge gets even more pronounced after transplantation when the islets become buried in blood clots and tissues.
We have recently shown that we can use a microscale tissue engineering system we previously developed to remake islets into smaller, size controlled "pseudoislets". These last longer than the islets from which they are made, and function effectively both in culture, and in mice with induced diabetes. In the work proposed here we will establish ways to generate our pseudoislets in the quantities that will be needed for research and to treat patients; we will create processes to freeze, store and deliver them when and where they are needed; and we will develop quality control procedures to ensure the material is reliably safe and effective.
Competitiondate
201809
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ungrin, Mark D
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~